Lucy Scientific Discovery (NASDAQ:LSDI) Stock Price Down 7.8%

Shares of Lucy Scientific Discovery Inc. (NASDAQ:LSDI) traded down 7.8% during trading on Friday . The company traded as low as $1.12 and last traded at $1.12. 30,592 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 45,516 shares. The stock had previously closed at $1.22.

Lucy Scientific Discovery Stock Performance

The business’s 50 day moving average is $1.63 and its 200 day moving average is $2.31. The company has a market capitalization of $1.97 million, a price-to-earnings ratio of -0.16 and a beta of 0.65.

Lucy Scientific Discovery (NASDAQ:LSDI) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.70) EPS for the quarter. The business had revenue of $9.68 million for the quarter.

Institutional Trading of Lucy Scientific Discovery

Several institutional investors and hedge funds have recently bought and sold shares of the business. Potomac Capital Management Inc. purchased a new stake in shares of Lucy Scientific Discovery during the first quarter worth $125,000. Walleye Capital LLC grew its holdings in shares of Lucy Scientific Discovery by 98.5% during the second quarter. Walleye Capital LLC now owns 77,853 shares of the company’s stock worth $90,000 after buying an additional 38,639 shares in the last quarter. Finally, AdvisorShares Investments LLC grew its holdings in shares of Lucy Scientific Discovery by 63.7% during the third quarter. AdvisorShares Investments LLC now owns 466,000 shares of the company’s stock worth $279,000 after buying an additional 181,276 shares in the last quarter. 72.61% of the stock is currently owned by institutional investors and hedge funds.

Lucy Scientific Discovery Company Profile

Lucy Scientific Discovery Inc, an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products.